The agreement covers 19 European markets, representing a total population of approximately 500 million people including all major EU countries and the United Kingdom as well as the eleven countries where Terclara is already approved but not yet launched. This provides Moberg Pharma the opportunity for a coordinated launch in all key European markets. Karo Healthcare will be responsible for marketing, distribution and sales throughout Europe. Financial terms are not disclosed, but the agreement includes royalties and compensation for delivered products.

“We are very pleased to enter this partnership with Karo Healthcare, which has a strong commercial presence across Europe. Launching MOB-015/Terclara under the well-known Lamisil®brand gives us an exceptional opportunity to establish the product as the market leader also beyond Sweden and Norway,” says Anna Ljung, CEO of Moberg Pharma.

“Moberg Pharma has developed a unique and clinically well-documented product. Being able to launch MOB-015/Terclara under the Lamisil brand is a perfect combination of scientific innovation and commercial strength that gives us a unique position in the market,” says Christoffer Lorenzen, CEO of Karo.